^Boue, S., Wiese, T., Nehls, S., Burow, M., Elliott, S., Carter-Wientjes, C., Shih, B., McLachlan, J., Cleveland, T. (2003). “Evaluation of the Estrogenic Effects of Legume Extracts Containing Phytoestrogens”. Journal of Agriculture and Food Science53 (8): 2193–2199. doi:10.1021/jf0211145.
^Lin LZ, He XG, Lindenmaier M, Yang J, Cleary M, Qiu SX, Cordell GA (2000). “LC-ESI-MS Study of the the Flavonoid Glycoside Malonates of Red Clover (Trifolium pratense)”. J. Agric. Food Chem.2 (48): 354-365. doi:10.1021/jf991002.
^Setchell, KD; Clerici, C; Lephart, ED; Cole, SJ; Heenan, C; Castellani, D; Wolfe, BE; Nechemias-Zimmer, L et al. (May 2005). “S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora”. en:The American Journal of Clinical Nutrition81 (5): 1072–9. PMID15883431.
^Iwasaki M, Inoue M, Otani T, Sasazuki S, Kurahashi N, Miura T, Yamamoto S, Tsugane S; Japan Public Health Center-based prospective study group (2008). “Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case-control study from the Japan Public Health Center-based prospective study group”. J. Clin. Oncol.26 (10): 1677-1683. doi:10.1200/JCO.2007.13.9964. PMID18316793.
^国立がん研究センターがん予防・検診研究センター 予防研究部 (2008年). “血中イソフラボン濃度と乳がん罹患との関係について”. JPHC Study 厚生労働省研究班による多目的コホート研究. 2011年3月10日閲覧。
^Trock BJ, Hilakivi-Clarke L, Clarke R (2006). “Meta-analysis of soy intake and breast cancer risk”. J. Natl. Cancer Inst.98 (7): 459–71. doi:10.1093/jnci/djj102. PMID16595782.
^Xie Q, Chen ML, Qin Y, et al. (2013). “Isoflavone consumption and risk of breast cancer: a dose-response meta-analysis of observational studies”. Asia Pac J Clin Nutr22 (1): 118–27. PMID23353619.
^Tse G, Eslick GD (2016). “Soy and isoflavone consumption and risk of gastrointestinal cancer: a systematic review and meta-analysis”. Eur J Nutr55 (1): 63–73. doi:10.1007/s00394-014-0824-7. PMID25547973.
^Zhang Q, Feng H, Qluwakemi B, Wang J, Yao S, Cheng G, Xu H, Qiu H, Zhu L, Yuan M (2017). “Phytoestrogens and risk of prostate cancer: an updated meta-analysis of epidemiologic studies”. Int J Food Sci Nutr68 (1): 28–42. doi:10.1080/09637486.2016.1216525. PMID27687296.
^Qu XL, Fang Y, Zhang M, Zhang YZ (2014). “Phytoestrogen intake and risk of ovarian cancer: a meta- analysis of 10 observational studies”. Asian Pac. J. Cancer Prev.15 (21): 9085–91. PMID25422183.
^Jiang R, Botma A, Rudolph A, Hüsing A, Chang-Claude J (2016). “Phyto-oestrogens and colorectal cancer risk: a systematic review and dose-response meta-analysis of observational studies”. Br. J. Nutr.116 (12): 2115–2128. doi:10.1017/S0007114516004360. PMID28091359.
^国立がん研究センターがん予防・検診研究センター 予防研究部 (2003年). “大豆・イソフラボン摂取と乳がん発生率との関係について”. JPHC Study 厚生労働省研究班による多目的コホート研究. 2011年3月10日閲覧。
^Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S; Japan Public Health Center-Based Prospective Study on Cancer Cardiovascular Diseases Group (2003). “Soy, isoflavones, and breast cancer risk in Japan”. J. Natl. Cancer. Inst.95 (12): 906-913. doi:10.1093/jnci/95.12.906. PMID12813174.
^国立がん研究センターがん予防・検診研究センター 予防研究部 (2007年). “イソフラボンと脳梗塞・心筋梗塞発症との関連について”. JPHC Study 厚生労働省研究班による多目的コホート研究. 2011年3月10日閲覧。
^Kokubo Y, Iso H, Ishihara J, Okada K, Inoue M, Tsugane S; JPHC Study Group (2007). “Association of dietary intake of soy, beans, and isoflavones with risk of cerebral and myocardial infarctions in Japanese populations: the Japan Public Health Center-based (JPHC) study cohort I”. Circulation116 (22): 2553-2562. doi:10.1161/CIRCULATIONAHA.106.683755. PMID18025534.
^国立がん研究センターがん予防・検診研究センター 予防研究部 (2007年). “大豆製品・イソフラボン摂取量と前立腺がんとの関連について”. JPHC Study 厚生労働省研究班による多目的コホート研究. 2011年3月10日閲覧。
^Kurahashi N, Iwasaki M, Sasazuki S, Otani T, Inoue M, Tsugane S; Japan Public Health Center-Based Prospective Study Group (2007). “Soy product and isoflavone consumption in relation to prostate cancer in Japanese men”. Cancer Epidemiol. Biomarkers Prev.16 (3): 538-545. doi:10.1158/1055-9965.EPI-06-0517. PMID17337648.
^Wei P, Liu M, Chen Y, Chen DC (2012). “Systematic review of soy isoflavone supplements on osteoporosis in women”. Asian Pac J Trop Med5 (3): 243–8. doi:10.1016/S1995-7645(12)60033-9. PMID22305793.
^Ricci E, Cipriani S, Chiaffarino F, Malvezzi M, Parazzini F (2010). “Soy isoflavones and bone mineral density in perimenopausal and postmenopausal Western women: a systematic review and meta-analysis of randomized controlled trials”. J Womens Health (Larchmt)19 (9): 1609–17. doi:10.1089/jwh.2010.2021. PMID20673147.
^Li L, Xu L, Wu J, Dong L, Zhao S, Zheng Q (2016). “Comparative efficacy of nonhormonal drugs on menopausal hot flashes”. Eur. J. Clin. Pharmacol.72 (9): 1051–8. doi:10.1007/s00228-016-2090-5. PMID27450233.
^Myers SP, Vigar V (2017). “Effects of a standardised extract of Trifolium pratense (Promensil) at a dosage of 80mg in the treatment of menopausal hot flushes: A systematic review and meta-analysis”. Phytomedicine24: 141–147. doi:10.1016/j.phymed.2016.12.003. PMID28160855.
^Tokede OA, Onabanjo TA, Yansane A, Gaziano JM, Djoussé L (2015). “Soya products and serum lipids: a meta-analysis of randomised controlled trials”. Br. J. Nutr.114 (6): 831–43. doi:10.1017/S0007114515002603. PMID26268987.